Numerous clinical trials are always open and enrolling patients in the ECOG-ACRIN Cancer Research Group, which focuses its research on adults 18 years of age and older who have or are at risk of developing cancer. The table below contains a list of all active clinical trials, with links to the educational and recruitment materials that are publicly available to patients and researchers.
The trials below are listed alphabetically by cancer type. To sort, hover over any of the column headings and click the up/down arrows. You can also search by keyword. To access the educational and recruitment material for a particular trial, click on the trial ID.
| Cancer Type | Trial ID/Educational Material | Target Patient Population |
|---|---|---|
| Various | EAQ202 | Ages 18-39 with any type of cancer except basal cell carcinoma |
| Various | EAQ222CD / CostCOM | Ages 18+ with any type of solid cancer of any stage |
| Various | EAY191 / ComboMATCH | Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally advanced) or other places in the body (advanced) |
| Various | EAY191-E5 / ComboMATCH-E5 | Metastatic (advanced) solid tumors with a KRAS G12C mutation |
| Bladder | EA8212 / BRIDGE | High risk; has not spread to the muscleĀ |
| Blood | EA9171 / BLAST MRD CML 1 | Chronic myelogenous leukemia (CML) |
| Blood | EA9181 | Acute lymphoblastic leukemia (ALL) |
| Blood | EA9213 | Acute lymphoblastic leukemia (ALL), T-cell Type |
| Blood | EAA173 / DETER-SMM | Smoldering myeloma |
| Blood | EAA181 / EQUATE | Myeloma, newly diagnosed |
| Blood | EAQ211 | Survivors of Hodgkin or Non-Hodgkin lymphoma, age 15-39 when diagnosed |
| Blood | MM1OA-EA02 / myeloMATCH | Acute myeloid leukemia (AML) |
| Brain | Glioblastoma, newly diagnosed | |
| Breast | EA1151 / TMIST | Women planning for regular mammograms |
| Breast | EA1211 / DIRECT | Early stage, HER2 positive type |
| Breast | EAQ221CD / CONCURxP | Metastatic (advanced) |
| Colorectal | EA2222 / PUMP | Metastatic (advanced to the liver), not able to be removed by surgery (inoperable) |
| Esophagus | EA2174 | Locally advanced, able to be removed by surgery (operable) |
| Esophagus and Stomach | EA2183 | Metastatic (advanced), HER2 negative type |
| Gallbladder | EA2197 / OPT-IN | Discovered at time of surgery to remove the gallbladder |
| Head and Neck | EA3132 | p53-mutated squamous cell type, after surgery |
| Head and Neck | EA3191 | Squamous cell carcinoma of the head and neck that has come back after initial therapy |
| Head and Neck | EA3202 | Metastatic (advanced) squamous cell type that has returned after treatment with immune checkpoint inhibitors |
| Head and Neck | EA3211 | Metastatic (advanced) squamous cell carcinoma |
| Kidney | EA8211 / SOAR | Metastatic (advanced) renal cell carcinoma |
| Lung | EA5162 | Non-small cell type, metastatic (advanced) |
| Lung | EA5182 | Non-small cell type, metastatic (advanced) |
| Lung | EA5221 / ACHIEVE | Non-small cell type, metastatic (advanced) |
| Melanoma (Skin) | EA6141 | Metastatic (advanced) |
| Melanoma (Skin) | EA6192 / PET-Stop | Metastatic (advanced) |
| Melanoma (Skin) | EA6194 | Able to be removed by surgery (operable) |
| Pancreas | EA2185 | Patients with non-cancerous pancreas cysts |
| Pancreas | EA2186 / GIANT | Metastatic (advanced), older (aged 70+) |
| Pancreas | EA2192 / APOLLO | Has been surgically removed and has a BRCA1, BRCA2, or PALB2 mutation |
| Penis | EA8134 / InPACT | Spread to nearby tissue or lymph nodes (locally advanced) |
| Prostate | EA8171 | Newly diagnosed, before surgery |
| Prostate | EA8184 | On close monitoring; at low risk of progressing |
| Prostate | EA8191 / INDICATE | Has come back after surgery |
| Rectum | EA2201 | Locally advanced, MSI-H or dMMR type |
| Sarcoma | EA7211 / STRASS 2 | Able to be removed by surgery (operable); at high risk of returning |
| Sarcoma | EA7222 | Metastatic (advanced), not able to be removed by surgery |
| Stomach | EA2212 | Gastric (stomach) and/or gastroesophageal junction cancer, able to be removed by surgery (operable) |
| Throat | EA3161 | HPV positive type |
| Thyroid | Differentiated and BRAF V600E-mutated type that has spread after standard treatment | |
| Upper Urinary Tract | EA8192 | High grade (aggressive) |
